

## Special Issue

# New Insights Into Non-Alcoholic Fatty Liver Diseases

### Message from the Guest Editors

Non-alcoholic fatty liver disease (NAFLD) poses a significant global health challenge, affecting patients across all age groups, from children to middle-aged and older adults, and is linked to diabetes and cardiovascular diseases. Clinical challenges, including underdiagnosis and the imperative for precise risk stratification, highlight the urgency of comprehending molecular mechanisms, population disparities, and metabolic pathways in the early stages of pathogenesis. This Special Issue delves into essential aspects, focusing on metabolic pathways influencing fatty liver, deciphering genetic contributions to pathogenesis, and exploring population-specific differences. Additionally, we illuminate the crucial role of various metabolic pathways in NAFLD pathogenesis, aiming to deepen our understanding of treatment options. Insights into nutritional interventions, the triglyceride glucose index, and genetic polymorphisms emerge as pivotal elements for addressing NAFLD progression, emphasizing the need for tailored nutritional programs and targeted pharmacological interventions.

### Guest Editors

Dr. Hazem Ayesh

Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN, USA

Dr. Robert Schierwagen

Department of Internal Medicine B, University of Münster, 48149 Münster, Germany

### Deadline for manuscript submissions

closed (31 July 2025)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/209698](https://mdpi.com/si/209698)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).